Darinaparsin: First Approval
Author:
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical)
Link
https://link.springer.com/content/pdf/10.1007/s40265-022-01795-z.pdf
Reference27 articles.
1. Fox CP, Ahearne MJ, Ruth P, et al. Guidelines for the management of mature T- and natural killer-cell lymphomas (excluding cutaneous T-cell lymphoma): a British Society for Haematology Guideline. Br J Haematol. 2022;196(3):507–22.
2. Lansigan F, Horwitz SM, Pinter-Brown LC, et al. Outcomes for relapsed and refractory peripheral T-Cell lymphoma patients after front-line therapy from the COMPLETE registry. Acta Haematol. 2020;143(1):40–50.
3. Quintás-Cardama A, Verstovsek S, Freireich E, et al. Chemical and clinical development of darinaparsin, a novel organic arsenic derivative. Anticancer Agents Med Chem. 2008;8(8):904–9.
4. Mann KK, Wallner B, Lossos IS, et al. Darinaparsin: a novel organic arsenical with promising anticancer activity. Expert Opin Investig Drugs. 2009;18(11):1727–34.
5. Fukuhara N, Kim WS, Yoon DH, et al. Asian multinational phase II study of darinaparsin in patients with relapsed or refractory peripheral T-cell lymphoma [abstract no. 1376]. Blood. 2021;138(Suppl 1):1376.
Cited by 10 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Nanovaccine of tumor-derived antigenic microparticles for enhancing effect of arsenic trioxide in cancer immunotherapy;Nano Today;2024-08
2. Synthesis and application of small molecules approved for the treatment of lymphoma;European Journal of Medicinal Chemistry;2023-12
3. Discovery of novel organoarsenicals as robust thioredoxin reductase inhibitors for oxidative stress mediated cancer therapy;Biochemical Pharmacology;2023-12
4. Reprogramming Energy Metabolism with Synthesized PDK Inhibitors Based on Dichloroacetate Derivatives and Targeted Delivery Systems for Enhanced Cancer Therapy;Journal of Medicinal Chemistry;2023-09-09
5. Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials;Signal Transduction and Targeted Therapy;2023-09-06
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3